New Drugs

Alemtuzumab, two-course infusion, approved for relapsing MS

Alemtuzumab, administered in two intravenous infusions over several days 1 year apart, has been ...

Nivolumab monotherapy reaches advanced squamous NSCLC

FROM A THORACIC ONCOLOGY SYMPOSIUM CHICAGO (FRONTLINE MEDICAL NEWS) – Nivolumab monotherapy resulted in ...

Dabrafenib and trametinib combo boosts melanoma survival

FROM THE SMR INTERNATIONAL CONGRESS The combination of dabrafenib and trametinib achieves significant improvements ...

Correction: Bevacizumab plus fosbretabulin in ovarian cancer

In an article titled “Bevacizumab plus fosbretabulin improves survival in ovarian cancer” (published November ...

Bevacizumab plus fosbretabulin improves survival in ovarian cancer

AT IGCS 2014 MELBOURNE (FRONTLINE MEDICAL NEWS) – The combination of the antiangiogenesis drug ...